Income rose again in the third quarter, to $717 million.

Its total users rose only 2 percent in the quarter, to 412 million.

Sales rose to $31.2 million in the first quarter of 2012.

Final sales rose at a 3.5 percent rate in the second quarter.

Sales of that drug rose 19 percent in the third quarter to $848 million.

That figure rose to 3.8 million in the final quarter of the year.

Sales rose 3.8 percent in the quarter to $2.54 billion.

Bad loans rose $65 million to $2.84 billion in the quarter.

Revenue rose 19.2 percent in the quarter to $1.05 billion.

Sales rose to $1.18 billion, from $925 million in the quarter a year earlier.